Condition

Stage IV Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 203 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials203

Recruiting2

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerNCT06678269 · 2024-11-15

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerNCT06439693 · 2024-08-08

Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNCT07687225 · 2026-09-01

NOT_YET_RECRUITING

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsNCT04985357 · 2024-11-01

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast CancerNCT05959291 · 2023-07-17

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08

ACTIVE_NOT_RECRUITING

Ask Questions (ASQ):Implementation of a Communication InterventionNCT05025748 · 2021-08-25

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast CancerNCT03749850 · 2021-03-01

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerNCT04670445 · 2021-01-23

Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic PatientsNCT05229575 · 2020-07-10

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer PatientsNCT04199520 · 2020-04-15

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor SitesNCT04267575 · 2019-07-30

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerNCT03971409 · 2019-07-08

ACTIVE_NOT_RECRUITING

Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of CyclophosphamideNCT06361264 · 2018-11-01

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV CancerNCT04113096 · 2018-10-01

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerNCT03566485 · 2018-07-10

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerNCT03455270 · 2018-05-09

Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast CancerNCT03683147 · 2017-12-13

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their PartnersNCT03112668 · 2017-12-06

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerNCT03364348 · 2017-10-30

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsNCT03070002 · 2017-10-19

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerNCT02892734 · 2017-09-18

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerNCT03213041 · 2017-09-14

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast CancerNCT03206203 · 2017-08-29

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerNCT03154190 · 2017-08-08

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerNCT03128619 · 2017-08-02

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerNCT02860000 · 2017-07-06

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryNCT03044730 · 2017-05-25

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast CancerNCT03139435 · 2017-05-11

Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer PatientsNCT03222258 · 2016-12-17

Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsNCT02897375 · 2016-10-24

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)NCT02728596 · 2016-10-07

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisNCT02774681 · 2016-08-31

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerNCT02824575 · 2016-07-01

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving TrastuzumabNCT00194714 · 2016-05-01

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerNCT02657889 · 2016-04-15

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerNCT02648477 · 2016-03-28

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerNCT02672475 · 2016-03-01

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635 · 2016-02-05

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerNCT02536794 · 2016-01-14

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsNCT02646319 · 2016-01-01

18F-FSPG PET/CT for Cancer Patients on TherapyNCT02599194 · 2015-07-01

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast CancerNCT02157051 · 2015-06-01

ACTIVE_NOT_RECRUITING

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerNCT02457910 · 2015-06-01

Oxaliplatin in Treating Patients With Metastatic Breast CancerNCT02077998 · 2015-05-01

Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast CancerNCT02331212 · 2015-03-01

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerNCT02226276 · 2015-01-07

ACTIVE_NOT_RECRUITING

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryNCT02219789 · 2014-12-05

Phase II Study of Everolimus Beyond ProgressionNCT02269670 · 2014-11-25

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerNCT02273752 · 2014-11-01

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving EverolimusNCT02015559 · 2014-10-08

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerNCT02120469 · 2014-10-01

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerNCT02206334 · 2014-08-01

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or LungNCT01741597 · 2014-07-01

BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast CancerNCT03603197 · 2014-06-05

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by SurgeryNCT01816035 · 2014-06-01

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane TxNCT02038010 · 2014-05-21

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerNCT01938833 · 2014-04-01

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerNCT02060253 · 2014-04-01

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody TherapyNCT01922921 · 2014-02-05

Common interventions

Leading sponsors

National Cancer Institute (NCI) 63 University of Washington 21 Northwestern University 9 City of Hope Medical Center 8 Mayo Clinic 6 University of Southern California 6 Vanderbilt-Ingram Cancer Center 6 Wake Forest University Health Sciences 6 Meabco A/S 5 Burzynski Research Institute 3 Emory University 3 Fred Hutchinson Cancer Center 3 Jonsson Comprehensive Cancer Center 3 University of Chicago 3 Dana-Farber Cancer Institute 2

Trial status mix

COMPLETED133

TERMINATED42

WITHDRAWN13

ACTIVE_NOT_RECRUITING6

UNKNOWN6

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE297

PHASE181

NA29

PHASE39

EARLY_PHASE17

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.